clear throughout the Abstracts and the Body of the proper instead of referring to them as "prescribed medications" 3.3Primary outcomes: 3.3.1 Mortality: line 14. Is it a requirement that the current GP practice is notified of death of their patient? If so, how long does notification usually take?. These questions are important for completeness of the record regarding mortality. If there is no regulation ensuring such notification, then this is a nother limitation of the study. 3.3.2 Physical functioning Lines 47-51: You state that patients who scored 3+ had 4 times........ compared with? (I assume those who scored lower scores?) You can't report a 4 x result, without giving the comparator. Please add the comparator group at the end of this sentence. 4. RESULTS 4.1 Participants I would have like to see some chi squares done on the patient characteristics between the groups. This may have identified inherent statistical differences that could have been used later for adjustment in development of a predictive model. Further, the binary nature of measures such as education level and social class, is simplistic. However, since you do not actually use these variables in any predictive model, they are acceptable. 4.2 Outcomes: 4.2.1 The outcomes are described as 'broadly similar" . What does this term mean exactly? 4.2.2 Again, since you are dealing with proportions why not apply chi squares to each outcome comparison between the groups and decide if they are statistically different? 4.2.3 When you report the sensitivity, specificity and, positive and negative predictive values (ref Table 3 ), you give a biased interpretation to the results. You ignore the 95% confidence intervals and merely present the best estimate. If you absorb table three you find: that --Sensitivity of MEDS and chronic disease count (CDC) do not differ for Death outcome, and that for each of the other outcome measures, CDC is more sensitive than Meds for each of the three outcomes. --Specificity: meds are better in all four outcomes: --PPV: there is no difference between the two in any of the 4 outcomes; --NPV: no difference between them in all four outcomes. 4.2.4 This also raises a question about your statistics: Did you adjust for the cluster sample study design (patients around 15 practices).? If you didn't, your CIs are more narrow than they should be, and in fact the differences I identified above may be proven non -existent if adjustment WAS applied to this analysis. So, if you DIDNT adjust for the cluster, you need to go back and do so. If the program DID adjust for the cluster sample study design then you need to report this in the methods. 5. DISCUSSION 5.1 Main findings This opening paragraph has the same problem as the approach you took in the results section. You are supposed to be doing a COMPARISON of the meds and CDC, yet not comparing them using the statistics you have provided in table 3. You then rely on the statically higher specificity of 10+ meds (the ability of 10+ meds to correctly identify those patients who will NOT have the outcomes measured), to conclude that 10+ meds is a better predictor than 3+ chronic diseases of poorer outcomes. This is illogical. Your description of the sensitivity is limited to a statement that both definitions had low sensitivity. One thing you could say about the results ( which you don't) is that there was no difference between the two in sensitivity for the 'death ' outcome. I keep feeling you described the results before you created the 95% CIs, and then just put the 95% CIs in the Table. If so, go back to Table 3 and reconsider the implications of the presented results. You are trying to measure which is different in terms of PPV and NPV,--for which there are no differences at all between the two processes of selection. So how can you conclude that.... because 10+meds has better SPECIFICIY and worse ( for most outcomes) SENSITIVITY... 10 + meds is 'better"? 5.2 Strengths and limitations 5.2.1. Line 53-55. How 'robust ' is medical record review? Literature suggests that medical record reviews can be limited by, incomplete date, poor disease labelling etc. It is improved when a structured coding system +/-classification of disease is applied. I think you should recognise, that completeness and accuracy of such data collected in thei manner, has some limitations. 5.2.2 In this section I remembered a study from Australia by Miller G et al, not yet published, but presented at NAPCRG in ( I think) 2016. It demonstrated a direct linear relationship between number of diagnosed chronic problems and number of medications. Age of the patient fell out of the model. This made me wonder, what overlap there was between the people who qualified for 10+ meds measure, and the people who qualified under the 3+ chronic disease measure? This is important, as it is highly likely that the 10+ meds groups is close enough to a sub-sample of the 3+ chronic disease group. Or, did you remove the 10+ meds group from the 3+ CDC group, and so there is NO overlap????The implications of this for the validity of your research needs careful consideration. 5.2.3. Considerung the literature on the effect of limiting the number of conditions stduied on the estimate of prevlence of multimorbidity ( whether counted as 2+ or 3+), you need to recognise the limiting effect of counting only 40 chronic disease. 6. Conclusion: I have already commented on the conclusion in the Discussion above. Tables: clear, though you need to add the denominator in the column headings please.
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GENERAL COMMENTS
Dear authors, thank you for the opportunity to review this manuscript on measurement of multimorbidity.
My main and pretty fundamental comment from a clinical perspective is the broad range between a disease count of 3 or more and a medication count of 10 or more which for me limits the value of the study. Wouldn't it have been possible and appropriate to look at different cutt off's for both measures rather then pragmatically following the advice in the literature about 3+ and 10+? I believe that using this approach would add to the value of the study and capture the criticism from a clinical perspective that 10+ medications is a much 'sicker' patient group then 3+ diseases.
I get the point of using sensitivity, specificity and positive and negative predictive value to compare the accuracy of the measures but I believe if the sensitivity (and specificity) are so low you should also discuss the important limitations and challenges of multimorbidity measurement. This is missing in the discussion in my opinion. I also believe you should extend your literature search as some publications in the field of predictive value of MM measurement seem to be missing. If that would be the conclusion of the study I think both the intro and the discussion should talk more about the different clinical interventions for MM and polypharmacy. This is an important weakness of the paper in it's current form which I think may be handled through a major revision.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 1. Abstract Clear but missing some vital information: it is not 10 + medications. It is 10+ medication classes Undefined). See comments later in this review, regarding Data collection section. Author response The NICE Multimorbidity Guidance does not specifically give that level of detail. We operationalized this using medication classes defined as per the first three characters of the WHO-ATC classification system which is now included in the methods section. We have also clarified that these are being used as multimorbidity measures rather than definitions. We have clarified this as follows in the abstract: "Multimorbidity is commonly defined using condition counts. The United Kingdom National Institute for Health Care Excellence (NICE) Guidelines for Multimorbidity suggest that a medication-orientated approach (identifying patients prescribed ≥10 regular medicines) could be used to identify those in need of a multimorbidity approach to management." 2. Introduction is adequate. Page 4. lines 34-39. You give hospital admission as an example of an 'additional risk factor" in the NICE Guidelines. It would be helpful if you included age ≥70 years old here as a further example for 'risk factors', since you use this as the added risk factor, without clearly stating this was a possibility in the first place. Author response We reviewed the NICE Guidance for clarity given this confusion around additional risk factors and it suggests the following which has been amended in the paper:
"The NICE Guidance suggests that the number of regular prescribed medicines can be used to identify those in need of such an approach with the advantage that this can be retrieved from the electronic health record. It suggests considering a multimorbidity approach to care for adults of any age who are prescribed ≥10 medications [13] . In this section your heading for the medication count is 'Medication classes prescribed to the patient", but throughout the paper you talk of "medications prescribed". Even in this paragraph you defined the cut-off as 10 + prescribed medications. This is not acceptable. If they are medication CLASSES. Please report the classification used in the data, and identify the level within the classification, at which you defined 'class". Also make it clear throughout the Abstracts and the Body of the proper instead of referring to them as "prescribed medications" Author response The medications classes classification was defined as the first three characters of the WHO-ATC medication classification system and this has now been clarified in the methods and throughout the manuscript. 4.2.2 Again, since you are dealing with proportions why not apply chi squares to each outcome comparison between the groups and decide if they are statistically different? Author response As above in relation to patient characteristics, we have tested for differences in outcomes for both exposures and added this to the manuscript -please see Table 2 .
4.2.3 When you report the sensitivity, specificity and, positive and negative predictive values (ref Table 3 ), you give a biased interpretation to the results. You ignore the 95% confidence intervals and merely present the best estimate. If you absorb table three you find: that --Sensitivity of MEDS and chronic disease count (CDC) do not differ for Death outcome, and that for each of the other outcome measures, CDC is more sensitive than Meds for each of the three outcomes.
--Specificity: meds are better in all four outcomes: --PPV: there is no difference between the two in any of the 4 outcomes; --NPV: no difference between them in all four outcomes. Author response We agree that the interpretations of results were unclear and we have completely revised and updated the results section and interpretation of the results based on the estimates and 95% confidence intervals for sensitivity, specificity, NPV and PPV.
This also raises a question about your statistics:
Did you adjust for the cluster sample study design (patients around 15 practices).? If you didn't, your CIs are more narrow than they should be, and in fact the differences I identified above may be proven non -existent if adjustment WAS applied to this analysis. So, if you DIDNT adjust for the cluster, you need to go back and do so. If the program DID adjust for the cluster sample study design then you need to report this in the methods. Author response We adjusted for clustering and have updated the methods and results section to clarify this.
DISCUSSION 5.1 Main findings
This opening paragraph has the same problem as the approach you took in the results section. You are supposed to be doing a COMPARISON of the meds and CDC, yet not comparing them using the statistics you have provided in table 3. You then rely on the statically higher specificity of 10+ meds (the ability of 10+ meds to correctly identify those patients who will NOT have the outcomes measured), to conclude that 10+ meds is a better predictor than 3+ chronic diseases of poorer outcomes. This is illogical. Author response We agree this was confusing and have revised the opening paragraph of the discussion in line with the revised interpretation of results (specifically in relation to Table 3 ).
Your description of the sensitivity is limited to a statement that both definitions had low sensitivity. One thing you could say about the results ( which you don't) is that there was no difference between the two in sensitivity for the 'death ' outcome. I keep feeling you described the results before you created the 95% CIs, and then just put the 95% CIs in the Table. If so, go back to Table 3 and reconsider the implications of the presented results. You are trying to measure which is different in terms of PPV and NPV,--for which there are no differences at all between the two processes of selection. So how can you conclude that.... because 10+meds has better SPECIFICIY and worse ( for most outcomes) SENSITIVITY... 10 + meds is 'better"? Author response As mentioned above, we have completely revised the interpretation of results and the discussion section.
Strengths and limitations
Line 53-55. How 'robust ' is medical record review? Literature suggests that medical record reviews can be limited by, incomplete date, poor disease labelling etc. It is improved when a structured coding system +/-classification of disease is applied. I think you should recognise, that completeness and accuracy of such data collected in thei manner, has some limitations. Author response We accept that there may be some variation in documentation in medical records. Data collection was carried out by eight medical students who completed a three-day training course before commencing data collection and used standardised data collection forms. We have added these issues as a potential limitation to the Discussion.
In this section I remembered a study from Australia by Miller G et al, not yet published, but presented at NAPCRG in ( I think) 2016. It demonstrated a direct linear relationship between number of diagnosed chronic problems and number of medications. Age of the patient fell out of the model. This made me wonder, what overlap there was between the people who qualified for 10+ meds measure, and the people who qualified under the 3+ chronic disease measure? This is important, as it is highly likely that the 10+ meds groups is close enough to a sub-sample of the 3+ chronic disease group. Or, did you remove the 10+ meds group from the 3+ CDC group, and so there is NO overlap????The implications of this for the validity of your research needs careful consideration. Author response The 10 more than medication classes group was not a sub-sample of the 3 or more chronic diseases group but there was an overlap, 61 patients had both 10 more than medication classes and 3 or more chronic diseases. We have added this detail into the results section.
Considering the literature on the effect of limiting the number of conditions studied on the estimate of prevalence of multimorbidity ( whether counted as 2+ or 3+), you need to recognise the limiting effect of counting only 40 chronic disease. Author response Given that many other papers in multimorbidity restrict eligibility to far fewer conditions, we do not think this is a major limitation but have added the following to the Limitations section of the discussion: "We limited the number of chronic conditions identified in the records to the 40 used in the Barnett study in 2012 and this could be seen as a limitation in that not all other less common conditions were included." Furthermore, a previous systematic review of prevalence studies reported that there was minimal variation in sampling once more than 12 conditions were included. Author response We have revised the conclusion and added the denominator to the tables.
Reviewer: 2 1. My main and pretty fundamental comment from a clinical perspective is the broad range between a disease count of 3 or more and a medication count of 10 or more which for me limits the value of the study. Wouldn't it have been possible and appropriate to look at different cut off's for both measures rather then pragmatically following the advice in the literature about 3+ and 10+? I believe that using this approach would add to the value of the study and capture the criticism from a clinical perspective that 10+ medications is a much 'sicker' patient group then 3+ diseases.
Author response
We agree that there may well be differences between patients identified by condition count compared to medication classes counts but both of these approaches have been suggested as ways to target those within the multimorbidity population for intervention. This is why our primary aim was simply to compare these two approaches in terms of their ability to identify those with poorer outcomes more accurately. Both cut-points were chosen based on the NICE Guidance and current literature and we did not think there was a sufficient sample size or rationale to test different cut-points.
2. I get the point of using sensitivity, specificity and positive and negative predictive value to compare the accuracy of the measures but I believe if the sensitivity (and specificity) are so low you should also discuss the important limitations and challenges of multimorbidity measurement. This is missing in the discussion in my opinion. I also believe you should extend your literature search as some publications in the field of predictive value of MM measurement seem to be missing. Author response Thank you, we agree that discussing the limitations of multimorbidity measurement is important and was only briefly discussed in the previous version of the manuscript. We have added the following to the revised manuscript: "Research to date has highlighted the limitations of multimorbidity measures when it comes to predicting adverse events and work in this area is ongoing."
We have also added the references suggested.
3. Another point is that when you look at risk prediction models I am not 100% sure that the sens/spec/PPV/NPV approach is a good one. In my opinion this is mostly used in diagnostic tests and I am not sure it stands for this kind of research questions but that is debatable.
Author response The goal of the study was not to elaborate a risk prediction model as such but to consider how the two multimorbidity measures performed in terms of sensitivity, specificity, PPV and NPV, given the recommendations that they could be used in a clinical setting to identify people at risk of declining health who could benefit from a multimorbidity approach of care.
4. In the introduction (p4.l22) you talk about a community based intervention. what do you mean? In the discussion of the abstract you talk about targeted clinical care. What do you mean? I think these statements about clinical impact have to be looked at throughout the paper because it feels as if this hasn't been discussed among the team well enough. It is important because the 10+ medication count (with additional risk of adverse events!) would mostly require interventions related to PIP and medication review. From a clinical perspective 'community based interventions or targeted clinical care' for multimorbidity may have a different outlook.
We accept that a medication focused intervention might be the most obvious consideration in the context of polypharmacy but our understanding of the medication count definition recommended by NICE is that it is to be used as a proxy for multimorbidity so in fact it may be that any other multimorbidity focused intervention would be appropriate for people identified using this approach. The following has been added to the Introduction to clarify this: "Polypharmacy such as this is a marker of multimorbidity so that patients identified this way can be regarded as having multimorbidity and offered broad interventions beyond medicines management" Author response The PROM selected for the analysis had all been dichotomized in previous publications. We have now made this process clearer in the methods section: "The PROMs selected were dichotomized, as described below to identify changes in outcome over time."
8. p8. 49-50 patientS or memberS?
Author response We have amended this to the plural as suggested.
9. RESULTS. as I said earlier I believe you could consider a different strategy of analysis as I am not sure that the paper in this version really adds to the literature.
Author response As mentioned previously, the goal of the study was to consider how the two multimorbidity measures performed in terms of sensitivity, specificity, PPV and NPV and whether they could be used in a clinical setting to identify people at risk of declining health who could benefit from a multimorbidity approach of care. We have revised the analysis and result sections to clarify the methods used and interpretation of results.
10. p22. l44-45. you talk about five continuous measures. I think you need to elaborate on that. it's not clear what you mean now and I think it is very relevant to consider if you think how measures of MM could support clinical care and identification of patients at risk. you have used a dicotomous measure, howo is this different from a continuous measure in terms of it's use in practice/policy Author response The dichotomous definitions used for the multimorbidity measures are based on the NICE clinical guidelines about the use of a cut-off in clinical setting to identify patients who would benefit a multimorbidity approach of care. We have added the following to the limitations section to address this comment: "Similarly, the sample size precluded an analysis of the measures performance if used as continuous compared to dichotomized measures."
11. Generally in the paper, I believe you should talk more about the range of outcomes you have. having self reported health is a major strength of this study and I feel as if these important data are drowning in the current draft. you also elaborate very little about this in the discussion comparing what you found about the relation between MM and different health related outcomes to the literature Author response We agree that the inclusion of both chart based and patient reported outcomes is a strength of our study and we have included this comment in the discussion section as follows: "A main strength of the study is that the dataset includes both mortality data, prescription data and patient-reported outcomes."
12. DISCUSSION and CONCLUSION. I agree that maybe we need to pragmatically use medication counts as a proxy for multimorbidity (and stop measuring MM???) . If that would be the conclusion of the study I think both the intro and the discussion should talk more about the different clinical interventions for MM and polypharmacy. This is an important weakness of the paper in it's current form which I think may be handled through a major revision.
The NICE Guidance recommendation to identify patients in need of an adapted approach to multimorbidity were added in the introduction. As in our response to a previous related reviewer comment, we have clarified that the medication classes count measure is a proxy for multimorbidity and identifies people who may benefit from more than a medicines management based intervention.
